ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced thyroid cancer (papillary, follicular, Hurthle cell, or poorly differentiated) that cannot be removed by surgery or radiation.
- Your cancer no longer responds to radioactive iodine treatment.
- You have tried at least one prior targeted therapy (TKI) and it stopped working or caused side effects.
- You are in generally good health with a performance status of 0 or 1 (able to do daily activities).
- Your thyroid hormone levels are well-controlled with medication (TSH less than 0.5).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
This study tests a new oral drug called ST-1898 for people with advanced acral melanoma that has not responded to standard treatments. It aims to see if the drug can shrink or slow the growth of the cancer.
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This trial is testing a new oral medication, XL092, for people with advanced thyroid cancer that has stopped responding to radioactive iodine therapy. The goal is to see if XL092 can slow or stop the cancer from growing.
Hear when a new Differentiated Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.